BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 38554946)

  • 21. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanobodies in Human Infections: Prevention, Detection, and Treatment.
    Sanaei M; Setayesh N; Sepehrizadeh Z; Mahdavi M; Yazdi MH
    Immunol Invest; 2020 Nov; 49(8):875-896. PubMed ID: 31856615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
    Kalman B; Szep E; Garzuly F; Post DE
    Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanobody-based cancer therapy of solid tumors.
    Kijanka M; Dorresteijn B; Oliveira S; van Bergen en Henegouwen PM
    Nanomedicine (Lond); 2015 Jan; 10(1):161-74. PubMed ID: 25597775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics.
    Naidoo DB; Chuturgoon AA
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
    J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer.
    Van Audenhove I; Gettemans J
    EBioMedicine; 2016 Jun; 8():40-48. PubMed ID: 27428417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies.
    Hrynchak I; Santos L; Falcão A; Gomes CM; Abrunhosa AJ
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Theranostics in immuno-oncology using nanobody derivatives.
    Lecocq Q; De Vlaeminck Y; Hanssens H; D'Huyvetter M; Raes G; Goyvaerts C; Keyaerts M; Devoogdt N; Breckpot K
    Theranostics; 2019; 9(25):7772-7791. PubMed ID: 31695800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanobodies-Useful Tools for Allergy Treatment?
    Flicker S; Zettl I; Tillib SV
    Front Immunol; 2020; 11():576255. PubMed ID: 33117377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanobody Conjugates for Targeted Cancer Therapy and Imaging.
    Kang W; Ding C; Zheng D; Ma X; Yi L; Tong X; Wu C; Xue C; Yu Y; Zhou Q
    Technol Cancer Res Treat; 2021; 20():15330338211010117. PubMed ID: 33929911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
    Goss GD; Spaans JN
    Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current status and future expectations of nanobodies in oncology trials.
    De Pauw T; De Mey L; Debacker JM; Raes G; Van Ginderachter JA; De Groof TWM; Devoogdt N
    Expert Opin Investig Drugs; 2023; 32(8):705-721. PubMed ID: 37638538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies.
    Tripathy RK; Pande AH
    Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours.
    Wang L; Zhang G; Qin L; Ye H; Wang Y; Long B; Jiao Z
    Recent Pat Anticancer Drug Discov; 2020; 15(3):200-211. PubMed ID: 32885759
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.